Neurotensin(8–13) analogue: radiolabeling and biological evaluation using different chelators
Abstract
Introduction
Several strategies on the development of radiopharmaceuticals have been employed. Bifunctional chelators seem to be a promising approach since high radiochemical yields as well as good in vitro and in vivo stability have been achieved. To date, neurotensin analogs have been radiolabeled using the 99mTc-carbonyl approach and none was described employing the bifunctional chelating agent technique.
Aim
The purpose of this study was to evaluate the radiochemical and biological behaviour of NT(8–13) analogue radiolabeled with 99mTc, using HYNIC and NHS-S-acetyl-MAG3 as chelator agents.
Methods
Radiolabeling, in vitro stability toward cysteine and glutathione, partition coefficient and plasma protein binding were assessed for both radioconjugates. Biodistribution in healthy Swiss mice were carried out in order to evaluate the biological behaviour of the radiocomplexes.
Results
Radiochemical yields were higher than 97% and no apparent instability toward transchelant agents was observed for both radioconjugates. A higher lipophilic character was observed for the radioconjugate labeled via MAG3. The chelators seem to have no effect on the percentage of the radioconjugate bound to plasma proteins. A similar biological pattern was observed for both radioconjugates. Total blood, bone and muscle values revealed a slightly slower clearance for the radiocomplex labeled via MAG3. Moreover, a remarkable liver and intestinal uptake was observed for the radiocomplex labeled via MAG3 even at the later time points studied.
Conclusion
The high radiochemical yields achieved and the similar in vivo pattern found for both radioconjugates make them potential candidates for imaging tumors using nuclear medicine techniques.
Keywords: Bifunctional chelating agents, Neurotensin analog, 99mTc
To access this article, please choose from the options below
PII: S0969-8051(10)00324-0
doi:10.1016/j.nucmedbio.2010.06.011
© 2011 Elsevier Inc. All rights reserved.
